Residency · Residency · Pediatrics

Primary Immunodeficiency: When to Suspect and How to Screen

Introduction

Primary immunodeficiencies (PIDs), now increasingly referred to as inborn errors of immunity (IEI), comprise over 480 distinct genetic disorders affecting the development or function of the immune system. Collectively, they are more common than previously recognized, affecting approximately 1 in 1,200 to 1 in 2,000 live births when including IgA deficiency. Early recognition is critical because delayed diagnosis leads to increased morbidity from recurrent and severe infections, end-organ damage, autoimmunity, and malignancy. The average diagnostic delay for PID is 5-7 years, highlighting the need for pediatricians to maintain a high index of suspicion.

Classification of Primary Immunodeficiencies

Antibody (B-cell) Deficiencies -- Most Common (50-60%)

Selective IgA deficiency is the most common PID, occurring in 1 in 300-700 individuals. It is often asymptomatic but can cause recurrent sinopulmonary infections and is associated with celiac disease and autoimmunity. Patients are at risk for anaphylaxis with blood products containing IgA. Common variable immunodeficiency (CVID) is a heterogeneous disorder with onset typically in the second or third decade, characterized by low IgG and low IgA and/or IgM. It presents with recurrent bacterial sinopulmonary infections and is associated with autoimmune cytopenias, granulomatous disease, lymphoid hyperplasia, and increased lymphoma risk. X-linked agammaglobulinemia (XLA, or Bruton's) results from mutations in the BTK gene and affects boys. It is characterized by absent B cells and all immunoglobulin classes, presenting at 6-9 months when maternal antibody wanes. Physical examination reveals absent or hypoplastic tonsils and lymph nodes. Transient hypogammaglobulinemia of infancy represents an exaggerated physiologic nadir of immunoglobulins that self-resolves by age 2-4 years and must be distinguished from true PID through monitoring.

Combined (T-cell and B-cell) Deficiencies (15-20%)

Severe combined immunodeficiency (SCID) is the most severe PID and has multiple genetic forms, with X-linked IL2RG being the most common, followed by ADA deficiency. It is characterized by absent or nonfunctional T cells with variable B and NK cell involvement. SCID presents in the first months of life with failure to thrive, chronic diarrhea, persistent oral candidiasis, and opportunistic infections including Pneumocystis jirovecii pneumonia, CMV, and disseminated BCG. SCID is a pediatric emergency because untreated disease is uniformly fatal within the first 1-2 years of life. Newborn screening for SCID using T-cell receptor excision circles (TRECs) is now performed in all 50 US states.

Phagocyte Defects (10-15%)

Chronic granulomatous disease (CGD) results from defective NADPH oxidase and an inability to kill catalase-positive organisms including Staphylococcus aureus, Aspergillus, Serratia, Nocardia, and Burkholderia cepacia. It causes recurrent deep-seated infections such as liver abscess, lymphadenitis, osteomyelitis, and pneumonia, and is diagnosed by dihydrorhodamine (DHR) flow cytometry or the nitroblue tetrazolium (NBT) test. Leukocyte adhesion deficiency (LAD) involves defective adhesion molecules and presents with delayed umbilical cord separation (greater than 30 days), leukocytosis without pus formation, poor wound healing, and omphalitis. Cyclic neutropenia follows a 21-day cycle of neutropenia with recurrent fevers and oral ulcers.

Complement Deficiencies (2-5%)

Early complement component deficiencies (C1, C2, C4) are associated with SLE-like disease and autoimmunity, with C2 deficiency being the most common complement deficiency. C3 deficiency causes recurrent pyogenic infections with encapsulated organisms. Terminal complement component deficiencies (C5-C9) lead to increased susceptibility to Neisseria meningitidis and N. gonorrhoeae, and recurrent meningococcal disease warrants complement evaluation. Mannose-binding lectin (MBL) deficiency is common (5-10% of the population) and causes a mild increase in infections, particularly in the setting of coexisting immune compromise.

Immune Dysregulation Syndromes

Autoimmune lymphoproliferative syndrome (ALPS) involves defective lymphocyte apoptosis and presents with lymphadenopathy, splenomegaly, and autoimmune cytopenias. IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) results from mutations in FOXP3 and presents in the neonatal period with diabetes, enteropathy, eczema, and autoimmune cytopenias.

<image>Classification diagram of primary immunodeficiencies organized by the affected arm of the immune system: B-cell/antibody deficiencies (with examples: IgA deficiency, CVID, XLA), combined T and B-cell deficiencies (SCID), phagocyte defects (CGD, LAD), complement deficiencies (terminal component deficiencies), and immune dysregulation syndromes, with the relative frequency of each category and age of typical presentation annotated</image>

When to Suspect a Primary Immunodeficiency

Jeffrey Modell Foundation Warning Signs (Modified)

The following 10 warning signs should prompt evaluation: four or more new ear infections within 1 year; two or more serious sinus infections within 1 year; two or more months on antibiotics with little effect; two or more pneumonias within 1 year; failure of an infant to gain weight or grow normally; recurrent deep skin or organ abscesses; persistent thrush or fungal infection on the skin after age 1 year; need for IV antibiotics to clear infections; two or more deep-seated infections such as meningitis, osteomyelitis, cellulitis, or sepsis; and a family history of primary immunodeficiency.

Additional Red Flags

Additional warning signs include infections with unusual or opportunistic organisms (Pneumocystis, atypical mycobacteria, Aspergillus, Cryptosporidium), adverse reactions to live vaccines (disseminated BCG, vaccine-strain polio, rotavirus-related illness), unexplained autoimmune cytopenias (autoimmune hemolytic anemia, ITP, autoimmune neutropenia), recurrent infections with the same organism type (suggesting a specific immune defect), and lymphopenia on a routine CBC in an infant, which should always prompt evaluation for SCID.

Screening and Diagnostic Workup

First-Tier Evaluation

The initial workup includes a CBC with differential, paying particular attention to the lymphocyte count (lymphopenia is a red flag for SCID in infants, with an absolute lymphocyte count below 2,500/mcL in infants warranting urgent evaluation) and the neutrophil count (for neutropenia and cyclic patterns). Quantitative immunoglobulins (IgG, IgA, IgM, IgE) should be compared to age-specific reference ranges, as immunoglobulin levels vary significantly by age. Specific antibody responses to vaccine antigens should be checked, including titers to protein antigens (tetanus, diphtheria) and polysaccharide antigens (pneumococcal serotypes); failure to mount a response suggests functional antibody deficiency. Complement screening includes CH50 (which screens the total classic pathway) and AH50 (alternative pathway), and if CH50 is zero, individual components should be measured.

Second-Tier Evaluation (Guided by Clinical Suspicion)

Second-tier testing includes lymphocyte subsets by flow cytometry (CD3+ T cells, CD4+, CD8+, CD19+ B cells, CD16/56+ NK cells), T-cell function testing with mitogen stimulation assays (PHA, ConA, PWM) and antigen stimulation (Candida, tetanus), DHR flow cytometry for suspected CGD (evaluating neutrophil oxidative burst), TREC assay (already performed at birth via newborn screening in all US states), and genetic testing through targeted gene panels, whole exome sequencing, or whole genome sequencing for definitive molecular diagnosis.

Newborn Screening for SCID

The TREC assay measures T-cell receptor excision circles, which are byproducts of T-cell receptor rearrangement in the thymus. Low or absent TRECs indicate T-cell lymphopenia and trigger urgent confirmatory evaluation. This screening has dramatically improved outcomes, as SCID detected by newborn screening and treated with hematopoietic stem cell transplant (HSCT) before 3.5 months has greater than 95% survival. False positives may occur in preterm infants, DiGeorge syndrome (22q11.2 deletion), cardiac surgery with thymectomy, and trisomy 21. False negatives are rare, but some T-cell deficiencies with preserved TREC generation may be missed.

<image>Stepwise diagnostic algorithm for evaluating a child with suspected primary immunodeficiency, starting from clinical warning signs through first-tier screening (CBC with differential, quantitative immunoglobulins, vaccine titers, CH50/AH50), followed by second-tier testing guided by suspected defect (lymphocyte subsets, proliferation assays, DHR, specific gene panels), with decision points leading to referral for immunology consultation and molecular diagnosis</image>

Management Principles

Immunoglobulin Replacement Therapy

Immunoglobulin replacement is indicated for significant antibody deficiencies including XLA, CVID, hyper-IgM syndrome, and SCID before definitive therapy. IVIG is given intravenously every 3-4 weeks with a target trough IgG greater than 500-800 mg/dL. SCIG (subcutaneous immunoglobulin) is administered weekly or biweekly as self-administration at home, provides steady-state levels, and has fewer systemic side effects. Lifelong therapy is required for most antibody deficiency states.

Antimicrobial Prophylaxis

TMP-SMX provides Pneumocystis prophylaxis in T-cell deficiencies and bacterial prophylaxis in CGD. Itraconazole or voriconazole provides antifungal prophylaxis in CGD. Azithromycin serves as prophylaxis for recurrent sinopulmonary infections in antibody deficiencies.

Definitive Therapy

Hematopoietic stem cell transplantation (HSCT) is curative for SCID, CGD, LAD, Wiskott-Aldrich syndrome, IPEX, and other severe PIDs, with best outcomes when performed early (before 3.5 months for SCID). Gene therapy is FDA-approved for ADA-SCID (Strimvelis), with clinical trials underway for X-linked SCID, CGD, and Wiskott-Aldrich syndrome. Thymus transplantation is available for complete DiGeorge syndrome (athymia).

Vaccine Considerations

Live vaccines are contraindicated in severe T-cell deficiencies (SCID, combined immunodeficiencies, some phagocyte defects), including MMR, varicella, rotavirus, live influenza, BCG, oral polio, and yellow fever. Inactivated vaccines are safe but may not generate protective responses in antibody-deficient patients. Household contacts should receive all routine vaccines (including live vaccines except oral polio) to provide cocooning protection.

Clinical Pearls

The average diagnostic delay for PID is 5-7 years, and a high index of suspicion with systematic screening can reduce this delay. Lymphopenia (ALC below 2,500/mcL) on a CBC in an infant is a red flag for SCID and requires urgent immunologic evaluation. Newborn screening for SCID using the TREC assay is now universal in the United States and has dramatically improved survival through early detection and HSCT. Recurrent Neisseria infections (meningococcal meningitis) should prompt evaluation for terminal complement deficiency. Infections with catalase-positive organisms (Staphylococcus, Aspergillus, Serratia) suggest chronic granulomatous disease. Immunoglobulin levels must always be compared to age-specific reference ranges, as adult ranges are not applicable to infants and young children.

References

1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. Journal of Clinical Immunology. 2022;42(7):1473-1507.
2. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology. 2015;136(5):1186-1205.
3. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
4. Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI) — diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunologic Research. 2011;51(1):61-70.

Read this lecture as Markdown